Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 11039895

Biologic therapy.

H Edington·S Agarwala·J M Kirkwood
View original source ↗Export metadata ↓

Abstract

Biologic therapy has evolved as a fourth treatment option for patients with melanoma and other malignancies. Interrelated advances in molecular diagnostics and gene therapy techniques will further accelerate therapeutic advances in this new arena. A variety of biologic therapeutic options available to the patient with high risk melanoma are reviewed.

Explore related subjects

Antibodies, MonoclonalBiological TherapyCytokinesHumansImmunotherapyInterferon-alphaInterferon-gammaInterleukinsLevamisoleLymphokinesMelanomaMonocytesMycobacterium bovisSkin NeoplasmsJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Edington, S Agarwala, J M Kirkwood. 2000. Biologic therapy.. https://pubmed.ncbi.nlm.nih.gov/11039895/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

ZrO₂@C-based colorimetric/photothermal dual-mode immunosensor coupled with a novel monoclonal antibody for quantification of Aspergillus ochraceus biomass.

Aspergillus ochraceus contaminates agricultural products and produces nephrotoxic, carcinogenic ochratoxin A (OTA), posing severe food safety hazards. A dual-signal lateral flow immunochromatographic assay (dLFIA) based on ZrO₂@C nanoprobes was established for quantitative detection of A. ochraceus biomass. A novel monoclonal antibody (mAb 4B4) was prepared as the capture antibody to immobilize A. ochraceus mycelial lysate antigen on the test line, and a rabbit polyclonal antibody (pAb G2801) as the detection antibody to modify ZrO₂@C composites (synthesized via UiO-66 pyrolysis) into 200 nm colorimetric/photothermal nanoprobes. This dLFIA achieved limits of detection of 0.164 μg/mL (colorimetric) and 0.517 μg/mL (photothermal). This efficient and reliable method allows quantitative analysis of A. ochraceus biomass, which is suitable for routine monitoring of fungal contamination in agro-food matrices.

Antibodies, Monoclonal↗
PubMed2002

Anti-IgE antibody therapy.

From the published studies of E25, it is now clear that this approach to treating atopic disease can be successful. But there remain many issues, both practical and biological. For the study of atopic disease, a potentially excellent new tool has been provided that could allow IgE to be effectively eliminated, given the correct-dosing regimen, and provide the investigator with a means to ask questions about the role of IgE in the expression of a particular disease. No place is this more evident than in the study of asthma for which a long-standing debate revolves around the precise contribution of atopy to the genesis and maintenance of this disease. Furthermore, use of the drug may finally resolve questions about the role of IgE in parasitic rejection. From the perspective of the patient, at a minimum, the drug provides a proof-of-concept for all potential therapies seeking to reduce circulating IgE levels. With proper consideration of dosing, the drug appears as if it could provide remarkable improvement in the course of atopic disease. Some concerns still revolve around the improvement roles IgE may play in parasitic diseases, the cost of therapy, and that very long-term treatment effects have yet to be studied.

Antibodies, Monoclonal↗
PubMed2001

The adhesion molecules, l-selectin and sialyl lewis x, relate to the formation of the follicular dendritic cell-lymphocyte cluster in the mantle zone.

The follicular dendritic cell (FDC)-lymphocyte cluster is rich in the follicular light zone of the secondary lymphoid follicles (LFs). Although, the mantle zone (MZ) also has FDC-lymphocyte cluster, it has not known about what kind of adhesion molecules relates to cluster formation. In the present study, we investigated whether the adhesion molecules, L-selectin (CD62L) and sialyl Lewis x (CD15s) can mediate the formation of the cluster in human tonsillar LFs. The MZ only expressed both the adhesion molecules in the secondary LF. Isolated FDC-lymphocyte clusters were composed of CD62L(+) lymphocytes and CD15s(+) FDCs. Stamper-Woodruff binding assay revealed that the binding of IgD(+) lymphocytes was significantly inhibited by pretreatment with anti-CD62L antibody or with anti-CD15s antibody. These results indicate that CD62L on MZ lymphocytes and CD15s on FDCs may play a role of the cluster formation, unlike the clusters in the other parts of LFs.

Antibodies, Monoclonal↗